Molecular profiling revealed concurrent <i>KRAS</i> and <i>CDK4</i> amplifications, providing a plausible mechanistic basis for the tumor's high proliferative index and aggressive behavior, and underscoring the biological heterogeneity underlying this rare presentation. This evidence concerns the gene KRAS and neoplasm.